X0306 4 2016-08-03 0 0001048477 BIOMARIN PHARMACEUTICAL INC BMRN 0001221590 BIENAIME JEAN JACQUES C/O BIOMARIN PHARMACEUTICAL INC. 770 LINDARO ST. SAN RAFAEL CA 94901 1 1 0 0 Chief Executive Officer Common Stock 2016-08-03 2016-08-03 5 G 0 400 0 D 378184 D Common Stock 2016-08-04 2016-08-04 5 G 0 500 0 D 377684 D Common Stock 2016-08-24 2016-08-24 5 G 0 200 0 D 377484 D Common Stock 2016-10-13 2016-10-13 4 M 0 53125 38.59 A 376493 D Common Stock 2016-10-13 2016-10-13 4 S 0 53125 86.9753 D 323368 D Common Stock 2016-10-14 2016-10-14 4 M 0 11000 17.86 A 334368 D Common Stock 2016-10-14 2016-10-14 4 S 0 11000 86.8922 D 323368 D Common Stock 25758 I Shares held by Bienaime Family Trust Stock Option (right to buy Common Stock) 38.59 2016-10-13 2016-10-13 4 M 0 53125 0 D 2008-11-22 2018-05-21 Common Stock 53125 212500 D Stock Option (right to buy Common Stock) 17.86 2016-10-14 2016-10-14 4 M 0 11000 0 D 2009-06-17 2018-12-16 Common Stock 11000 11000 D On August 3, 2016, the reporting person gifted 400 shares to an educational institution. On August 4, 2016, the reporting person gifted 500 shares to an educational institution. On August 24, 2016, the reporting person gifted 200 shares to an educational institution. Trade made pursuant to a 10b5-1 plan executed on June 9, 2016. Mr. Bienaime's former spouse will receive the net proceeds from the shares sold in this transaction in connection with cash payments owed to her pursuant to a martial separation agreement between her and Mr. Bienaime. The number of shares reflects transfers made by Mr. Bienaime to his former spouse prior to October 13, 2016, of a total of 54,116 shares pursuant to a marital separation agreement. The price in column 4 is the weighted average price. The price actually received ranged from $86.15 to $88.23. The reporting person shall provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price. The price in column 4 is the weighted average price. The price actually received ranged from $86.41 to $87.78. The reporting person shall provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price. Reflects the number of stock options outstanding after the transaction from this specific stock option grant. /s/ Laura Randall Woodhead, Attorney-in-Fact 2016-10-17